QSAR of human factor Xa inhibitor N2-aroylanthranilamides using principal component factor analysis

Drug Design and Discovery

Volumn 18, Issue 1, 2002, Pages 23-31

  Roy, Kunal ^a   De, A U ^a   Sengupta, Chandana ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Factor analysis; Factor Xa inhibitor; Hansch model; N2 aroylanthranilamides; QSAR

Indexed keywords

AMMONIUM SULFATE; BLOOD CLOTTING FACTOR 10A INHIBITOR; METHYL GROUP; N2 AROYLANTHRANILAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ARTICLE; BINDING AFFINITY; CORRELATION COEFFICIENT; DRUG ACTIVITY; DRUG STRUCTURE; ELECTRON; FACTORIAL ANALYSIS; HUMAN; HYDROPHILICITY; LIPOPHILICITY; PHYSICAL CHEMISTRY; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTHRANILIC ACIDS; ANTITHROMBIN III; HUMANS; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036933836     PISSN: 10559612     EISSN: None     Source Type: Journal    
DOI: 10.1080/10559610213503     Document Type: Article

References (15)

1. Hammer, R.H. (1995). Anticoagulants, coagulants and plasma extenders. In Principles of Medicinal Chemistry, edited by W. O. Faye, T. L. Lemke, and D. A. Williams, New Delhi, India, B. I. Waverly Pvt. Ltd.,, pp. 388-404.
2. Majerus, P. W., Broze, G. J., Jr., Miletich, J. P., and Tollefsen, D. M. (1995). Anticoagulant, thrombolytic and antiplatelet drugs. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, edited by J. G. Hardman and L. E. Limbard, New York, McGraw-Hill, pp. 1341-1359.
3. Smyth, R. D., Perigard, C. P., and Smyth, R. J. (1995). Clinical analysis. In Remington: The Science and Practice of Pharmacy, edited by A. R. Gennaro, Pennsylvania, Mack Publishing Co., pp. 501-533.
4. Herron, D. K., Goodson, T., Jr., Wiley, M. R., Weir, L. C., Kyle, J. A., Yee, Y. K., Tebbe, A. L., Tinsley, J. M., Mendel, D., Masters, J. J., Franciskovich, J. B., Sawyer, J. S., Beight, D. W., Ratz, A. M., Milot, G., Hall, S. E., Klimkowski, V. J., Wikel, J. H., Eastwood, B. J., Towner, R. D., Gifford-Moore, D. S., Craft, T. J., and Smith, G. F. (2000). 1,2-Dibenzamidobenzene inhibitors of human factor Xa. J. Med. Chem., 43, 859-872.
5. Al-Obeidi, F., and Ostrem, J. A. (1998). Factor Xa inhibitors by classical and combinatorial chemistry. Drug Discovery Today, 3, 223-231.
6. Sanderson, P. E. J. (1999). Noncovalent serine protease inhibitors. Med. Res. Rev., 19, 179-197.
7. 2-Aroylanthranilamide inhibitors of human factor Xa. J. Med. Chem., 43, 873-882.
8. Franke, R. (1984). Theoretical Drug Design Methods, Amsterdam, Elsevier, pp. 184-195.
9. Franke, R., and Gruska, A. (1995). Principal component and factor analysis. In Chemometric Methods in Molecular Design, Vol. II, edited by H. van de Waterbeemd, Weinheim, Germany VCH, pp. 113-163.
10. Snedecor, G. W., and Cochran, W. G. (1967). Statistical Methods, New Delhi, India, Oxford & IBH Publishing Co. Pvt. Ltd., pp. 381-418.
11. Kier, L. B., and Hall, L. H. (1992). Atom description in QSAR models: Development and use of an atom level index. Adv. Drug Design, 22, 1-38.
12. Wold, S., and Errikson, L. (1995). Validation tools. In Chemometric Methods in Molecular Design, edited by H. van de Waterbeemd, Weinheim, Germany, VCH, pp. 309-318.
13. MINITAB is a statistical software of Minitab Inc., New York.
14. The GW-BASIC programs RRR98, KRPRES1 and KRPRES2 were developed by Kunal Roy (1998) and Standardized on known data sets.
15. Kubinyi, H. (1995). The quantitative analysis of structure activity relationships. In Burger's Medicinal Chemistry and Drug Discovery, 5th ed., Vol. I, edited by M. E. Wolff, New York, John Wiley & Son, pp. 507-509.